- cafead   Oct 29, 2021 at 11:12: AM
via Gilead Sciences and Merck have signed an agreement to assess the efficacy of Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) to treat patients with metastatic triple-negative breast cancer (TNBC).
article source
article source